Pinebridge Investments L.P. Sells 1,450 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pinebridge Investments L.P. reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 89,190 shares of the company's stock after selling 1,450 shares during the quarter. Pinebridge Investments L.P. owned approximately 0.11% of IDEXX Laboratories worth $36,875,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of IDXX. United Capital Financial Advisors LLC lifted its position in shares of IDEXX Laboratories by 0.9% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after buying an additional 22 shares during the last quarter. Cranbrook Wealth Management LLC boosted its position in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after purchasing an additional 25 shares during the period. Gabelli Funds LLC increased its stake in shares of IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its position in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares during the period. Finally, Summit Trail Advisors LLC boosted its holdings in IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after buying an additional 26 shares during the period. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded down $3.54 during trading on Friday, hitting $437.44. 939,265 shares of the stock traded hands, compared to its average volume of 632,645. The stock has a market cap of $35.45 billion, a price-to-earnings ratio of 41.00, a PEG ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The firm's fifty day moving average is $419.93 and its 200-day moving average is $429.42.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IDXX shares. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.